Investigation for polymorphism of serotonin 3 receptors to the side effect after treatment with milnacipran and sertraline

Investigation for polymorphism of serotonin 3 receptors to the side effect after treatment with milnacipran and sertraline - Investigation for polymorphism of the side effect after treatment with milnacipran and sertraline

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004667

Enrollment

200

Registered

2011-01-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depression

Interventions

Drug:Milnacipran Period:8 weeks Dose:dose according to drug information Drug:Sertraline Period:8 weeks Dose:dose according to drug information

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients that the total point of the item (No. 1-17) of the Hamilton depressive scale (HAMD) are more than 18 point, and the depressive mood score is more than 2 point.

Exclusion criteria

Exclusion criteria: The patients have a heavy suicidal idea. The patients have severe physical diseases.

Design outcomes

Primary

Measure	Time frame
Hamilton's Rating Scale for Depression SF-36	—

Secondary

Measure	Time frame
The UKU side effect rating scale	—

Countries

Japan

Contacts

Public ContactKenichi Osada

St. Marianna University School of Medicine Neuropshyciatry

k2osada@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026